In this episode, we talk to Jeff Holder and Adam Siebert, Partners and Managing Directors at L.E.K. Consulting, about the rapidly evolving world of advanced drug modalities. With years of experience advising clients across the life sciences industry, Jeff and Adam sit at the intersection of cutting-edge science and the real-world constraints of getting medicines to patients. Together, we unpack the past, present and future of advanced drug modalities, the science and the strategic impl...
All content for Cures & Capital is the property of Martin Slezak and Simon Birksø and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, we talk to Jeff Holder and Adam Siebert, Partners and Managing Directors at L.E.K. Consulting, about the rapidly evolving world of advanced drug modalities. With years of experience advising clients across the life sciences industry, Jeff and Adam sit at the intersection of cutting-edge science and the real-world constraints of getting medicines to patients. Together, we unpack the past, present and future of advanced drug modalities, the science and the strategic impl...
Scott Berry on Rethinking Clinical Trials: Bayesian Design, Adaptivity, and Smarter Decisions
Cures & Capital
1 hour 19 minutes
1 month ago
Scott Berry on Rethinking Clinical Trials: Bayesian Design, Adaptivity, and Smarter Decisions
In this episode, we talk to Scott Berry, President and Senior Statistical Scientist at Berry Consultants - a pioneer in adaptive and Bayesian clinical trial design. With more than 25 years of experience designing trials for pharma, biotech, and government agencies, Scott has helped reshape how we think about learning in drug development. We explore what it really means to “learn as you go” in clinical trials - from the limitations of the traditional frequentist model to the promise of adapti...
Cures & Capital
In this episode, we talk to Jeff Holder and Adam Siebert, Partners and Managing Directors at L.E.K. Consulting, about the rapidly evolving world of advanced drug modalities. With years of experience advising clients across the life sciences industry, Jeff and Adam sit at the intersection of cutting-edge science and the real-world constraints of getting medicines to patients. Together, we unpack the past, present and future of advanced drug modalities, the science and the strategic impl...
